Asset Details
Do you wish to reserve the book?
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
Do you wish to request the book?
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
2017
Overview
Influenza epidemics cause substantial morbidity. The seasonal vaccine, an important control measure, is not completely efficacious. This trial assessed the efficacy of a recombinant seasonal vaccine (made in a cell culture rather than with viruses grown in eggs).
Reducing the burden of influenza disease requires improved vaccines, and a recombinant influenza vaccine may contribute to this public-health goal.
1
This vaccine contains recombinant hemagglutinin (HA) proteins produced in a serum-free medium by
expres
SF+ cells. These cells contain recombinant baculovirus vectors carrying genes that code for HA. The process yields recombinant HA that is genetically identical to the selected influenza strains without extraneous egg proteins, formaldehyde, antibiotics, or preservatives. Influenza viruses are grown in eggs to produce the inactivated influenza vaccine (IIV); these viruses typically contain mutations in the genes that code for HA that may reduce vaccine effectiveness. . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Female
/ Humans
/ Influenza A virus - isolation & purification
/ Influenza A Virus, H3N2 Subtype - isolation & purification
/ Influenza B virus - isolation & purification
/ Influenza Vaccines - adverse effects
/ Influenza Vaccines - immunology
/ Influenza, Human - prevention & control
/ Male
/ Vaccines
